Gilead Sciences (GILD): Jefferies Positive On ASK1 PhII

November 15, 2016 7:59 AM EST
Get Alerts GILD Hot Sheet
Price: $72.42 -0.58%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade GILD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Gilead Sciences (NASDAQ: GILD) while attending AASLD, where detailed data from the positive ph.II study of ASK1 inhibitor '4997 were presented. While the small study and still evolving NASH diagnosis/treatment paradigm limit full assessment of ‘4997’s opportunity, overall the detailed data favorably answered several remaining outstanding questions and support the view--based on data analysis and prior KOL feedback--that ‘4997, like much of GILD’s pipeline, is underappreciated.

No change to the price target of $91.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $76.75 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

Jefferies & Co

Add Your Comment